



PRODUCT: **XPOVIO®**

COMPANY: Karyopharm Therapeutics Inc.

**THERAPEUTIC AREA & INDICATION:**

Treatment of relapsed/refractory (RR) multiple myeloma and RR diffuse large B-cell lymphoma

---

**ABOUT THE PRODUCT**

XPOVIO® (selinexor) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins. XPOVIO received accelerated FDA approval in July 2019 in combination with dexamethasone for the treatment of adult patients with penta-refractory multiple myeloma. Karyopharm's sNDA requesting an expansion of its current indication to include the treatment for patients with multiple myeloma after at least one prior line of therapy has also been accepted for filing by the FDA. In June 2020, XPOVIO received accelerated FDA approval for its second indication in adult patients with relapsed or refractory diffuse large B-cell lymphoma after at least 2 lines of systemic therapy.